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An immune stimulating complex 
(ISCOM) subunit rabies vaccine 
protects dogs and mice against street 
rabies challenge 
M. Fekadu*ll~ J.H. Shaddock*, J. Ekstr6m*, A. Osterhaus *, D.W. Sanderlin*, 
B. Sundquist ,~and B. Morein* 
Dogs and mice were immunized with either a rabies glycoprotein subunit vaccine 
incorporated into an immune stimulating complex (ISCOM) or a commercial human 
diploid cell vaccine (HDCV) prepared from a Pitman Moore ( PM) rabies vaccine strain. 
Pre-exposure vaccination of mice with two in traperitoneal ( i.p. ) doses of 360 ng ISCOM 
or 0.5 ml HDCV protected 95% (38/40) and 90% (36/40) of mice, respectively, against 
a lethal intracerebral (i.c.) dose with challenge virus strain (CVS). One 360 ng i.p. dose 
of ISCOM protected 87.5% (35/40) of mice against i.c. challenge with CVS. Three 
groups of five dogs were vaccinated intramuscularly ( i.m.) with 730 ng of rabies ISCOM 
prepared from either the PM or the CVS rabies strains, and they resisted lethal street 
rabies challenge. Postexposure treatment of mice with three or four 120 ng i.m. doses of 
ISCOM protected 90% (27/30) and 94% (45/48), respectively, of mice inoculated in 
the footpad with street rabies virus, but three doses of HDCV conferred no protection. 
When .four doses of HDCV were administered postexposure, 78% (32/41) of the mice 
died of anaphylactic shock; 21% (11/52) of mice had already died of rabies 4 days after 
the third vaccine dose was administered. 
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INTRODUCTION 
Rabies is endemic in most of the world, and rabid dogs 
are responsible for >90% of human rabies deaths 1'2. 
Various types of human and animal vaccines are used 
worldwide for the prevention of rabies. These vaccines 
are prepared from brain tissue of adult or newborn 
animals 3-6, avian tissues v-9, or cell cultures 1°-11. The 
virus strains used for vaccine production are usually 
derived from the Pasteur fixed rabies virus strain, and 
the virus is usually inactivated by physical or chemical 
methods a 13. In humans, rabies vaccines are used for 
both pre- and postexposure immunization, whereas in 
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animals only pre-exposure vaccination is practised. 
Although the immunological basis of protection following 
vaccination with inactivated or live attenuated rabies 
virus vaccines is still not fully understood, it has been 
shown that both humoral and cellular immune responses 
are induced by rabies virus vaccines 14~16. 
Rabies virus particles contain five different proteins. 
Closely associated with the nucleoprotein (N) are the 
non-structural (NS) protein and the virion transcriptase 
(L). The N-protein represents he group-specific antigen 
of the genus. The matrix (M) protein and the glycoprotein 
(G) are located in a lipoprotein envelope, through which 
spikes of G protein project 17-19. Spike G-proteins are 
amphiphilic proteins with at least one subunit of the 
oligomeric protein inserted into the lipid bilayer of the 
viral envelope anchoring the spike to the membrane z°. 
For rabies virus and most other enveloped viruses, 
the spike G-proteins are the antigens responsible for 
stimulating virus-neutralizing antibody 21-26. It has also 
been shown that the N-protein (through another 
mechanism) can induce a protective immune response 
against rabies infection in animals zT'2s. 
One of the crucial points in eliciting immunity and 
protection is the effective presentation of the desired 
antigens in a vaccine. To date, relatively little attention 
has been paid to the physical form in which antigens 
should be presented to the immune system. Since it 
is now possible to isolate spike proteins as single 
peplomers from virion or through recombinant-DNA 
techniques, more immunogenic forms of presentation 
have become available such as protein micelles, virosomes, 
or the recently described immune stimulating complexes 
(ISCOMs). In addition, antigenically and physically 
defined subunit vaccines can now be formulated15,~ 6,29-33. 
Although protein micelles or liposomes containing 
multiple copies of virus G-protein have been shown to 
have considerable immunogenicity 34'35, this immuno- 
genicity largely depends on the addition of suitable 
adjuvant 36. 
The ISCOM structure was developed to create a well 
defined submicroscopic particle, one that presents everal 
copies of antigen exposed on a built-in saponin adjuvant 
(Quil-A)35'37-39. ISCOMs containing one or more viral 
envelope proteins of more than 20 different membrane 
viruses belonging to eight different virus families have 
been prepared ; all were shown to be highly immunogenic 
in various animal species, and they induced high 
protective immunity and good T-cell response 3v'4°-44. 
This report presents data on the serological response and 
protection from challenge in animals immunized with 
either an ISCOM containing the rabies G-protein or with 
a commercial human diploid cell rabies vaccine. 
MATERIALS  AND METHODS 
ISCOM preparation 
ISCOMS 35'45 were prepared from either the Pitman 
Moore (PM) or the challenge virus standard (CVS) 
rabies strains. Briefly, to ~ 200 mg purified virus in 8 ml 
TN-buffer (0.05 M Tris-hydrochloride, pH 7.4, 0.1 M 
NaCI), 0.9 ml of a stock solution of detergent Mega-10 
(decanoyl-N-methylglucamide) (Sigma)* was added to 
a final concentration of 2% and left for 2 h at room 
temperature. The solubilized virus was layered on top of 
10% sucrose in TN buffer containing 0.2% Mega-10 
(w/v), which was layered on 30% sucrose in TN buffer. 
The solubilized virus was concentrated at 30000 rev 
min -1 for 2h at 20°C in a TST 41.14 rotor. The top 
fraction consisting of the sample volume plus the 10% 
sucrose layer was collected and Quil-A was added to a 
final concentration of0.1%. The mixture was extensively 
dialysed for 72 h against three changes of TN buffer at 
room temperature. 
For comparative purposes a commercial human 
diploid cell vaccine (HDCV) (Imovax, lot no. Z-1355) 
prepared from the PM strain, and a reference rabies 
vaccine prepared from CVS (kindly supplied by National 
Veterinary Laboratory, Iowa, USA) served as controls. 
Purification of ISCOM by lectin affinity chromatography 
Approximately 40 mg purified rabies virus was 
solubilized in 175 ml of 1% Triton X-100 solution and 
the viral G-protein was purified by affinity chromato- 
graphy on a lentil lectin-conjugated Sepharose CL-4B 
column (Pharmacia Fine Chemicals, Uppsala, Sweden). 
The solubilized virus material was applied to the lectin 
column and equilibrated with TN-buffer containing 1% 
* Use of trade name or commercial sources i for identification ly 
and does not imply endorsement by he Public Health Services or the 
US Department of Health and Human Services 
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Triton X-100, and the unbound material was washed out 
of the column with 10 volumes of TN-buffer. Mega-10 
was then introduced into the column at a concentration 
of 0.05% in TN buffer. Material specifically bound to 
the lectin column was eluted with 0.2 r,! methyl 
glycopyranoside issolved in TN-buffer, containing 0.5% 
Mega-10. After elution peak, fractions were pooled and 
concentrated by a 30 K cut-off ultrafiltration device 
(Filtron) to a final volume of 25 ml. To this concentration 
4 mg lipid was added from a stock solution containing 
10mg cholesterol and 10mg phosphatidyl choline 
dissolved in water with 20% Mega-10. Quil-A was added 
to a final concentration of 0.1%, and the mixture was 
dialysed for 3 days against hree changes of TN-buffer, 
pH 7.4, at room temperature. The formation of ISCOM 
was confirmed by determination of the S-value 46 in 
sucrose gradient centrifugation by negative contrast 
electron microscopy of the gradient fractions. 
Animals 
All animals used in this experiment were raised in 
closed colonies at the Centers for Disease Control animal 
breeding facility. None of the dogs had been previously 
vaccinated against rabies, and none had rabies virus- 
neutralizing antibodies (VNA) at the time of inoculation 
(vaccination). 
Determination of antigenic values 
The National Institutes of Health (NIH) potency 
test 4v was used to determine and standardize the 
antigenic values of the ISCOMs, HDCV and reference 
vaccine 48. In brief, mice were vaccinated twice intra- 
peritoneally (i.p.) at a one-week interval with fivefold 
dilutions of each antigen. The vaccinated mice, along 
with groups of unvaccinated control mice, were then 
challenged intracerebrally (i.e.) with 30-100 mouse 
intracerebral lethal dose 50% (MICLDs0) ofCVS 1 week 
after the last vaccination. All test antigens were then 
diluted to obtain similar antigenic values for use in the 
protection experiments. 
Determination of VNA titres 
VNA titres in sera collected from experimental nimals 
were determined by the rapid fluorescent focus inhibition 
test (REFIT)49. Results were expressed in international 
units (IU) using an international standard reference 
serum 49. 
Immunofluorescence 
All dog sera were also tested for anti-nucleocapsid 
antibody titre by the indirect fluorescent antibody (IFA) 
technique using fluorescein-conjugated rabbit anti-dog 
globulin. 
Pre-exposure vaccination of mice 
Groups of 4-week-old female CDs-ICR mice were 
vaccinated i.p. on days 0 and 7 with 0.5 ml containing 
360 ng Gp of the respective ISCOM preparations, 0.5 ml 
(containing 2.5 IU) HDCV, or the reference vaccine prior 
to i.e. challenge with 103.2 MICLD5o CVS on day 14. 
All mice were observed for 30 days, and the number of 
dead animals was recorded aily. 
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Postexposure vaccination of mice 
To mimic the postexposure treatment of rabies 
infection, groups of mice were injected in the left hind 
footpad (FP) with 0.03 ml containing 100-200 FPLDso 
of street rabies (MD 5951) isolated from the salivary 
gland of a dog in Mexico. The mice were then vaccinated 
with 0.1 ml HDCV or 0.1 ml ISCOM preparation 
containing 120 ng once on day 0 (24 h postinjection 
(PI);  three times (days 0, 3 and 7); or four times (days 
0, 3, 7 and 14 PI). HDCV was given either three times 
(days 0, 3 and 7) or four times (days 0, 3, 7 and 14 PI). 
The animals were checked aily for clinical signs of rabies. 
Pre-exposure vaccination of dogs 
Twenty laboratory-raised beagles, 1 to 3 years of age 
and of either sex, were divided into four groups of five 
dogs each. Each dog was vaccinated i.m. in the hind leg. 
Group 1 was vaccinated with 1 ml containing 5 IU PM 
whole-virus suspension; groups 2, 3 and 4 were 
vaccinated with corresponding amounts (730ng) of 
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Figure I Geometric mean of rabies VNA titres of dogs vaccinated with 
whole virus or tSCOM preparations and then challenged with street 
rabies virus. The VNA induced by the ISCOM preparations was 
significantly higher (p < 0.012) than that induced by the whole virus. 
The prechallenge VNA titres of dogs vaccinated with PM ISCOMs was 
significantly higher (p < 0.021) than those vaccinated with CVS ISCOM 
preparations. In general the postbooster response of dogs vaccinated 
with ISCOMs was higher than those vaccinated with whole virus, 
particularly for CVS groups (p < 0.021). The VNA response after 
challenge of dogs vaccinated with either ISCOM preparation was similar 
(p > 0.750). ( - - - - ) ,  PM ISCOM; ( - - ) ,  CVS ISCOM; ( ..... ), CVS ISCOM 
(purified); ( . . . . .  ), PM whole virus 
Table 1 Mortality of mice vaccinated intraperitoneally with either one 
or two doses of G-ISCOM or two doses of HDCV (7 days apart) and 
challenged intracerebrally with challenge virus strain (CVS) 
Group Vaccine No of doses Inoculated Deaths (%) 
1 ISCOM 1 40 5 (125) a 
2 ISCOM 2 40 2 (50) a 
3 HDCV 1 40 25 (62.5) ~ 
4 HDCV 2 40 4 (10.0) ~ 
5 Control 0 40 38 (95.0) b 
~p < 0.05 compared with groups 3 and 5. 
°p < 0.001 compared with groups 1, 2 and 4 
Table 2 Mortality of mice inoculated in the footpad with a street rabies 
virus and then vaccinated intramuscularly with either ISCOM or HDCV 
Group Vaccine No. of doses Inoculated Deaths (%) 
1 ISCOM 1 30 16 (533) b 
2 ISCOM 2 30 3 (100) c 
3 ISCOM 3 48 3 (62) c 
4 HDCV 3 30 21 (700) ~ 
5 HDCV a 4 41 32 (78.0) ~ 
6 Control 0 30 22 (73.3) b 
"Eleven out of 52 mice died of rabies before the fourth vaccine dose; of 
the remaining 41 mice, 32 died of anaphylactic shock when the fourth 
dose was administered 
~p < 0.001 compared with groups 2 and 3 
Cp < 0.001 compared with groups 1, 4, 5 and 6 
strains. Serum specimens were collected at 30, 60 and 90 
days for determination of VNA titres against CVS and 
street rabies virus strains. At the end of the 90-day 
observation period, all dogs, including five unvaccinated 
control beagle dogs, were challenged in the masseter 
muscle with 1 ml of canine salivary gland suspension 
containing 106.3 (MICLDso) of a street rabies virus 
obtained from a dog near the Texas Mexico border 
(L-2596). Five days postchallenge, serum specimens were 
collected to determine the possible booster effect of the 
challenge virus. 
RESULTS 
Pre-exposure vaccination of mice 
Since pre-exposure vaccination of dogs with either PM 
or CVS ISCOM preparations yielded a high level of 
immune response (Figure I), the PM ISCOM was 
selected for comparison with the HDCV prepared from 
the same virus strain. 
Ninety-five percent (38/40) of mice survived i.e. 
challenge after vaccination with two i.p. doses of ISCOM 
containing 360 ng rabies G-protein, and 90% (36/40) of 
mice vaccinated with two i.p. doses of 0.5 ml HDCV also 
survived. The difference in efficacy between two doses of 
ISCOM or HDCV was not significant (p > 0.1). Of the 
mice that received only one 360 ng i.p. ISCOM or 0.5 ml 
HDCV dose, 87.5% (35/40), and 37.5% (15/40), 
respectively, also survived and the difference between 
these vaccines is significant (p < 0.05) ( Table 1 ). 
Postexposure vaccination of mice 
Of the 30 mice injected in the footpad with street rabies 
virus and vaccinated with three 0.1 ml doses of HDCV, 
most showed signs of rabies 2 days after the third vaccine 
dose. Twenty-one out of 30 vaccinated mice died of 
rabies, whereas only three of the 30 mice treated with 
three doses (120 ng) of ISCOM died. The difference in 
protection values between three doses of either vaccine 
is statistically significant (p < 0.001) (Table 2). 
In a second group of 52 mice that received three 0.1 ml 
i.m. doses of HDCV, 11 (21%) died of rabies 4 days 
after the third dose was administered. When the fourth 
HDCV dose was administered on day 14, 32 of the 
remaining 41 mice (78%) died, with no signs or severe 
reaction, of generalized convulsion (anaphylactic shock) 
occurring immediately after their inoculation (Table 2). 
Only three out of 48 challenged mice (6%) died after 
receiving four 120 ng i.m. doses of ISCOM, and 16 out 
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of 30 mice (53%) administered one dose of 120ng 
ISCOM. Protection values of three doses of HDCV or 
one dose of ISCOM were not significantly different from 
the negative control (p > 0.1) (Table 2). 
Pre-exposure vaccination of dogs 
All dogs vaccinated with an ISCOM, regardless of 
the virus strain used for preparation of the ISCOM, and 
those vaccinated with whole virus were protected against 
a street rabies virus challenge, whereas all unvaccinated 
control dogs died of rabies. Pre- and postchallenge rabies 
VNA titres of dogs are depicted in Figure 1. Although 
the antigenic value of the ISCOM preparations and the 
whole virus inoculum were similar, the VNA induced 
by the ISCOM preparations was significantly higher 
(p < 0.012) (Figure 1 ). The geometric mean prechallenge 
VNA titre (GMT) of dogs immunized with PM Whole 
virus vaccine (group 1 ) was 0.230 IU (range 0.2-0.4 IU), 
whereas the postchallenge titre was 1.222 IU (range 
0.1-9.3 IU). The geometric mean prechallenge VNA titre 
of dogs vaccinated with the ISCOM prepared from PM 
virus (group 2) was 2.289 IU (range 0.9 5.7 IU), and 
the postchallenge titre was 9.359 IU (range 2.0-3.86 IU) 
(Figure I ). The prechallenge VNA of dogs in group 2 
was significantly higher (p < 0.021) than in groups 3 
and 4. In general the booster esponse of dogs vaccinated 
with ISCOMs was higher than those vaccinated with 
whole virus, particularly for groups 3 (p <0.021 ) and 4 
(p < 0.021). The booster response of dogs vaccinated 
with ISCOM preparations was similar (p > 0.750). 
Five dogs vaccinated with whole virus (group 1 ) had 
a low detectable anti-N titre whereas the remaining 15 
dogs given ISCOMs were negative (data not shown), 
indicating that the rabies G-protein preparation used in 
this experiment was relatively pure and did not induce 
any detectable amounts of antinucleocapsid antibody. 
D ISCUSSION 
Limited information exists on experimental subunit 
rabies vaccines. However, recently rabies virus G-protein 
vaccinia recombinant vaccines have been successfully 
used to immunize animals 5°, and rabies G-protein 
presented in a virosome was also shown to be more 
immunogenic than that presented as protein micelle or 
killed vaccine 51. 
In the present experiment, ISCOM vaccines prepared 
from two different rabies virus strains were compared 
with conventional human rabies vaccine in animal 
models (dogs and mice). No obvious differences in VNA 
response or protection were observed between the 
lectin-purified or the crude detergent-solubilized CVS 
ISCOM preparations, but the PM ISCOM had higher 
VNA titre than CVS, especially at 90 days after 
vaccination. One dose of 0.73 pg of either of the ISCOMs 
induced significantly higher VNA titre than a whole virus 
vaccine with similar antigen value. Most remarkable was 
the high anamnestic response in animals vaccinated with 
the ISCOMs and then challenged with a street rabies 
virus, signifying that a memory cell response was induced. 
The efficacy of rabies vaccination has been shown in 
animals many times, and appears to correlate with the 
presence and degree of neutralizing-antibody titre 26'52. 
In some experiments, however, it has been documented 
that animals that fail to elicit neutralizing-antibody titre 
ISCOM subunit rabies vaccine: M. Fekadu et al. 
after exposure to viral antigen may resist rabies virus 
challenge 53, whereas others which had neutralizing- 
antibody titre succumbed 26"54. ISCOM-borne antigens 
induce cell-mediated immunity (CMI) efficiently 41 and 
they are unique (as shown with HIV-1 and influenza 
viral antigens) in their capacity to induce cytotoxic 
T-lymphocytes (CTL) which are CD8 + and under the 
restriction of MHC class 1. This class of CTL has been 
shown to confer protection against many membrane 
viruses, indicating that CMI to rabies virus might also 
be important for protection 55'56. 
Unlike other human viral vaccines, rabies vaccines are 
mainly used for postexposure treatment of exposed 
individuals, and the induction of virus-neutralizing 
antibody has been the parameter measured in judging 
the protection against rabies 52. In humans and animals, 
however, administration ofvaccine alone has rarely been 
demonstrated to prevent disease, unless anti-rabies serum 
(or globulin) was administered simultaneously 6'~'1°'51' 
57-59. Protective postexposure effect is not conferred by 
anti-rabies serum alone, indicating that vaccine activates 
protective mechanisms besides the neutralizing-antibody 
response 51'57-61. Whether the protection provided by 
postexposure immunization is to a greater or lesser extent 
dependent on CMI is not known. However, it is shown 
that ISCOMs containing the F-protein of measles virus 
efficiently induce CMI in mice including the TH1 type of 
cells which after adoptive transfer provided protection 
against i.e. virus challenge. These cells also produced 
IL-2 and gamma interferon 4°. It was also shown 
that envelope proteins of influenza virus and HIV-1 
incorporated in ISCOMs induce IL-2 gamma interferon 
producing cells more efficiently in mice than micelles of 
the same antigen. In the case of influenza virus, ISCOMs 
were more efficient than the live virus (B. Morein, 
unpublished ata). 
In the present study, three 120 ng rabies G-protein 
ISCOM doses administered postexposure protected 90% 
of rabies-infected mice, whereas HDCV gave no protection, 
even though both antigens were prepared from the same 
vaccine strain. Two ISCOM doses were equally effective, 
indicating that rabies ISCOMs are effective in post- 
exposure treatment of mice without the additional 
application of anti-rabies globulin. The use of commercial 
vaccine, however, was not only ineffective in post- 
exposure treatment of rabies-infected mice but also 
caused fatal hypersensitivity reaction similar to the 
systemic allergic reactions, ranging from hives to 
anaphylactic shocks, reported in humans in both pre- and 
postexposure immunization 6z 65. Thus, with ISCOM 
vaccines it may be possible eventually to eliminate 
antiserum from postexposure abies treatment, avoiding 
the expense and adverse reactions 6~ 6s. 
We have demonstrated that very low quantities of 
rabies G-proteins incorporated into ISCOM (without 
the additional application of anti-rabies globulin) protect 
mice against lethal rabies challenge when administered 
as a postexposure vaccine. Rabies ISCOM and whole 
virus vaccines were also successfully used for pre- 
exposure vaccination of dogs. Human postexposure 
immunization with ISCOMs may be possible, especially 
in areas where anti-rabies globulins may not be available 
for economic or technical reasons. Postexposure trials in 
other primates and other laboratory animals may 
be carried out to determine whether ISCOM subunit 
vaccines can be recommended for use in humans. 
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